Literature DB >> 12716775

Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones.

Deborah J Griggs1, Herida Marona, Laura J V Piddock.   

Abstract

Fluoroquinolone-resistant mutants were selected from Staphylococcus aureus NCTC 8532 (F77), and two GrlA mutants of F77 (F193 and F194) with moxifloxacin, sparfloxacin, ofloxacin, grepafloxacin, levofloxacin and trovafloxacin. For mutants selected from F77, moxifloxacin, grepafloxacin and sparfloxacin selected preferentially for mutations in gyrA (Glu-88-->Lys). Ofloxacin and trovafloxacin selected most commonly for mutations in grlA, conferring substitutions for Ser-80. Three mutants of F77 were shown to have substitutions in both GrlA (Phe-80) and GyrA (Lys-88). Of the mutants selected from F193 (GrlA Phe-80), restriction fragment length polymorphism analysis of gyrA showed that 76/94 had a mutation at codon 84; those analysed in detail all had the substitution Ser-->Leu. Two mutants selected with grepafloxacin contained the substitution Lys-88. One mutant selected with trovafloxacin contained a novel mutation in gyrA substituting Gly-82-->Cys. Of the mutants selected from F194 (GrlA Tyr-80), 6/8 had a mutation in gyrA codon 84; of which three contained Leu. The MICs of most agents for mutants selected from F193 and F194 were similar, irrespective of the mutation selected. No mutants had any changes in grlB, and only one had a mutation in gyrB giving rise to the novel substitution Asp-437-->His. The mutations arising in first-step mutants were influenced by the fluoroquinolone used for selection. The phenotypes and genotypes of second-step mutants, derived from mutants with existing mutations in grlA, were similar, regardless of the selecting antibiotic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716775     DOI: 10.1093/jac/dkg241

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

Authors:  Vito Ricci; Marnie L Peterson; John C Rotschafer; Hannah Wexler; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.

Authors:  Trudy H Grossman; Douglas J Bartels; Steve Mullin; Christian H Gross; Jonathan D Parsons; Yusheng Liao; Anne-Laure Grillot; Dean Stamos; Eric R Olson; Paul S Charifson; Nagraj Mani
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.

Authors:  Paul A Wickman; Jennifer A Black; Ellen Smith Moland; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by CmeB or CmeF.

Authors:  Lilian Pumbwe; Luke P Randall; Martin J Woodward; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

6.  Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.

Authors:  Yee Gyung Kwak; Que Chi Truong-Bolduc; Hong Bin Kim; Kyoung-Ho Song; Eu Suk Kim; David C Hooper
Journal:  J Antimicrob Chemother       Date:  2013-08-08       Impact factor: 5.790

7.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.

Authors:  Jijun Cheng; Jane A Thanassi; Christy L Thoma; Barton J Bradbury; Milind Deshpande; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

8.  A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic.

Authors:  Matthew T G Holden; Li-Yang Hsu; Kevin Kurt; Lucy A Weinert; Alison E Mather; Simon R Harris; Birgit Strommenger; Franziska Layer; Wolfgang Witte; Herminia de Lencastre; Robert Skov; Henrik Westh; Helena Zemlicková; Geoffrey Coombs; Angela M Kearns; Robert L R Hill; Jonathan Edgeworth; Ian Gould; Vanya Gant; Jonathan Cooke; Giles F Edwards; Paul R McAdam; Kate E Templeton; Angela McCann; Zhemin Zhou; Santiago Castillo-Ramírez; Edward J Feil; Lyndsey O Hudson; Mark C Enright; Francois Balloux; David M Aanensen; Brian G Spratt; J Ross Fitzgerald; Julian Parkhill; Mark Achtman; Stephen D Bentley; Ulrich Nübel
Journal:  Genome Res       Date:  2013-01-08       Impact factor: 9.043

9.  Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.

Authors:  Darlene Miller
Journal:  Clin Ophthalmol       Date:  2008-03

10.  Staphylococcus argenteus from rabbits in Thailand.

Authors:  Nitaya Indrawattana; Natapol Pumipuntu; Nawarat Suriyakhun; Arunee Jangsangthong; Suphang Kulpeanprasit; Narisara Chantratita; Nitat Sookrung; Wanpen Chaicumpa; Shutipen Buranasinsup
Journal:  Microbiologyopen       Date:  2018-06-21       Impact factor: 3.139

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.